Aviva
NBIX icon

Aviva’s Neurocrine Biosciences NBIX Stock Holding History

Aviva’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.39M Buy
71,310
+887
+1% +$118K 0.02% 546
2025
Q4 		$9.99M Buy
70,423
+3,784
+6% +$548K 0.02% 544
2025
Q3 		$9.35M Buy
66,639
+4,893
+8% +$663K 0.02% 542
2025
Q2 		$7.76M Buy
61,746
+56,420
+1,059% +$6.47M 0.02% 560
2025
Q1 		$589K Sell
5,326
-56,592
-91% -$7.17M ﹤0.01% 727
2024
Q4 		$8.45M Buy
61,918
+37,826
+157% +$4.68M 0.02% 472
2024
Q3 		$2.78M Sell
24,092
-39,459
-62% -$5.41M 0.01% 522
2024
Q2 		$8.75M Sell
63,551
-1,411
-2% -$194K 0.02% 451
2024
Q1 		$8.96M Buy
64,962
+5,994
+10% +$819K 0.03% 461
2023
Q4 		$7.77M Buy
58,968
+44,182
+299% +$5.09M 0.03% 472
2023
Q3 		$1.66M Buy
+14,786
New +$1.56M 0.01% 642
2022
Q4 		– Sell
-18,036
Closed -$1.92M – 1020
2022
Q3 		$1.92M Sell
18,036
-37,919
-68% -$3.85M 0.01% 712
2022
Q2 		$5.45M Buy
+55,955
New +$5.16M 0.03% 567
2022
Q1 		– Sell
-21,787
Closed -$1.86M – 1088
2021
Q4 		$1.86M Buy
+21,787
New +$2M 0.01% 872
2021
Q2 		– Sell
-13,950
Closed -$1.36M – 940
2021
Q1 		$1.36M Buy
13,950
+750
+6% +$78.6K 0.01% 740
2020
Q4 		$1.26M Sell
13,200
-9,622
-42% -$929K 0.01% 826
2020
Q3 		$2.19M Buy
22,822
+4,623
+25% +$535K 0.01% 753
2020
Q2 		$2.22M Sell
18,199
-22,144
-55% -$2.45M 0.01% 744
2020
Q1 		$3.49M Buy
40,343
+23,615
+141% +$2.31M 0.03% 609
2019
Q4 		$1.8M Buy
+16,728
New +$1.75M 0.01% 823
2014
Q3 		– Sell
-124,427
Closed -$1.85M – 845
2014
Q2 		$1.85M Buy
+124,427
New +$1.76M 0.01% 738
2014
Q1 		– Sell
-209,624
Closed -$1.96M – 820
2013
Q4 		$1.96M Buy
209,624
+3,226
+2% +$31.5K 0.02% 692
2013
Q3 		$2.34M Buy
206,398
+1,879
+0.9% +$25.8K 0.02% 651
2013
Q2 		$2.74M Buy
+204,519
New +$2.51M 0.03% 515

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aviva's NBIX Position: Q1 2026 in Review

Aviva increased its Neurocrine Biosciences (NBIX) stake by 1.3% in Q1 2026, buying an estimated $118K and bringing the position to 71,310 shares worth $9.39M. The position accounts for 0.02% of the portfolio, ranked #546.

Aviva first reported a position in NBIX in Q2 2013 and has held it in 24 quarters since. The position peaked at $9.99M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Aviva held 71,310 shares of Neurocrine Biosciences worth $9.39M as of Q1 2026.
  • Aviva bought 887 Neurocrine Biosciences shares in Q1 2026, an estimated $118K.
  • Neurocrine Biosciences made up 0.02% of Aviva's portfolio in Q1 2026, its #546 holding.
  • Aviva first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 24 quarters since.
  • Aviva's Neurocrine Biosciences position peaked at $9.99M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.